193 related articles for article (PubMed ID: 26863927)
1. Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.
Martinello R; Milani A; Geuna E; Zucchini G; Aversa C; Nuzzo A; Montemurro F
Expert Opin Investig Drugs; 2016; 25(4):393-403. PubMed ID: 26863927
[TBL] [Abstract][Full Text] [Related]
2. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
3. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
4. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
5. Investigational platelet-derived growth factor receptor kinase inhibitors in breast cancer therapy.
Criscitiello C; Gelao L; Viale G; Esposito A; Curigliano G
Expert Opin Investig Drugs; 2014 May; 23(5):599-610. PubMed ID: 24597540
[TBL] [Abstract][Full Text] [Related]
6. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Hamid O
J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
[TBL] [Abstract][Full Text] [Related]
7. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
[TBL] [Abstract][Full Text] [Related]
8. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to the combination of MEK and AKT inhibitors.
Kirouac DC; Du JY; Lahdenranta J; Overland R; Yarar D; Paragas V; Pace E; McDonagh CF; Nielsen UB; Onsum MD
Sci Signal; 2013 Aug; 6(288):ra68. PubMed ID: 23943608
[TBL] [Abstract][Full Text] [Related]
9. Complexity of signal transduction mediated by ErbB2: clues to the potential of receptor-targeted cancer therapy.
Nagy P; Jenei A; Damjanovich S; Jovin TM; Szölôsi J
Pathol Oncol Res; 1999; 5(4):255-71. PubMed ID: 10607920
[TBL] [Abstract][Full Text] [Related]
10. Flotillin depletion affects ErbB protein levels in different human breast cancer cells.
Asp N; Pust S; Sandvig K
Biochim Biophys Acta; 2014 Sep; 1843(9):1987-96. PubMed ID: 24747692
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
Motoyama AB; Hynes NE; Lane HA
Cancer Res; 2002 Jun; 62(11):3151-8. PubMed ID: 12036928
[TBL] [Abstract][Full Text] [Related]
12. The ErbB/HER receptor protein-tyrosine kinases and cancer.
Roskoski R
Biochem Biophys Res Commun; 2004 Jun; 319(1):1-11. PubMed ID: 15158434
[TBL] [Abstract][Full Text] [Related]
13. Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.
Strickler JH; Yoshino T; Graham RP; Siena S; Bekaii-Saab T
JAMA Oncol; 2022 May; 8(5):760-769. PubMed ID: 35238866
[TBL] [Abstract][Full Text] [Related]
14. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
[TBL] [Abstract][Full Text] [Related]
15. Controlled activation of ErbB1/ErbB2 heterodimers promote invasion of three-dimensional organized epithelia in an ErbB1-dependent manner: implications for progression of ErbB2-overexpressing tumors.
Zhan L; Xiang B; Muthuswamy SK
Cancer Res; 2006 May; 66(10):5201-8. PubMed ID: 16707444
[TBL] [Abstract][Full Text] [Related]
16. Early clinical development of epidermal growth factor receptor targeted therapy in breast cancer.
Matsuda N; Lim B; Wang X; Ueno NT
Expert Opin Investig Drugs; 2017 Apr; 26(4):463-479. PubMed ID: 28271910
[TBL] [Abstract][Full Text] [Related]
17. Elevated expression of erbB3 confers paclitaxel resistance in erbB2-overexpressing breast cancer cells via upregulation of Survivin.
Wang S; Huang X; Lee CK; Liu B
Oncogene; 2010 Jul; 29(29):4225-36. PubMed ID: 20498641
[TBL] [Abstract][Full Text] [Related]
18. Afatinib in the treatment of breast cancer.
Hurvitz SA; Shatsky R; Harbeck N
Expert Opin Investig Drugs; 2014 Jul; 23(7):1039-47. PubMed ID: 24870559
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
20. Signal transduction of erbB receptors in trastuzumab (Herceptin) sensitive and resistant cell lines: local stimulation using magnetic microspheres as assessed by quantitative digital microscopy.
Friedländer E; Arndt-Jovin DJ; Nagy P; Jovin TM; Szöllosi J; Vereb G
Cytometry A; 2005 Oct; 67(2):161-71. PubMed ID: 16163699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]